Third quarter 2015 results

Oslo, 28 October 2015

Weifa ASA: Third quarter 2015 results

Weifa ASA (OSE: WEIFA) maintained high market share in all key segments during third quarter 2015, and delivered continued good operations. Total revenues for the quarter amounted to NOK 77.0 million, in line with consumer health revenues for the year earlier period. It was the first full quarter as a pure consumer health company following the spin-off of its B2B operations and tablet manufacturing in the second quarter of 2015.

EBITDA was NOK 16.9 million, before NOK 1.8 million in the calculated cost of employee options, corresponding to an adjusted EBITDA margin of 21.9 percent. Total consumer health revenues in the first nine months of 2015 were NOK 235 million, representing an increase of approximately 5 percent from the same period last year. Nine-month EBITDA came to NOK 48.5 million before option cost of NOK 4.9 million, corresponding to an adjusted EBITDA margin of 20.6 percent.

"Weifa is on track to deliver revenue growth and improved EBITDA margin in 2015. We are satisfied with our first quarter as a pure consumer health company, maintaining a high market share in our key categories and continuing our track-record for innovation by introducing Bronkyl forte to drive growth in the cough and cold segment", says CEO Kathrine Gamborg Andreassen.

Weifa will give a presentation today at 08:30 CET at Felix Konferansesenter, Bryggetorget 3, Oslo, Norway. CEO Kathrine Gamborg Andreassen and CFO Simen Nyberg-Hansen will represent the company. The presentation will also be webcast live and can be accessed directly from:

Weifa is Norway's leading consumer health company. We supply real value through medicines, lifestyle products and solutions that address the essential needs of consumers, customers and professional partners. Weifa was founded in 1940 and now employs about 30 highly qualified people at our headquarters in Oslo. The company has a strong position in Norway and is the market leader in pain relief, with well-established brands such as Paracet and Ibux. We are also present in other key areas such as dietary supplements and treatment for colds and respiratory problems. Weifa is listed on the Oslo Børs (ticker WEIFA). For further information, please visit: www.weifa.no